Trexquant Investment LP Purchases Shares of 7,237 Arcellx, Inc. (NASDAQ:ACLX)

Trexquant Investment LP purchased a new stake in Arcellx, Inc. (NASDAQ:ACLX - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 7,237 shares of the company's stock, valued at approximately $555,000.

Other institutional investors also recently made changes to their positions in the company. Wellington Management Group LLP raised its position in shares of Arcellx by 15.2% in the third quarter. Wellington Management Group LLP now owns 20,968 shares of the company's stock valued at $1,751,000 after buying an additional 2,768 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Arcellx by 4.3% during the third quarter. Geode Capital Management LLC now owns 974,967 shares of the company's stock worth $81,434,000 after buying an additional 39,781 shares during the last quarter. Lord Abbett & CO. LLC lifted its stake in shares of Arcellx by 2.1% in the 3rd quarter. Lord Abbett & CO. LLC now owns 891,848 shares of the company's stock valued at $74,478,000 after acquiring an additional 18,004 shares during the last quarter. Avanza Fonder AB bought a new stake in Arcellx during the 4th quarter worth $184,000. Finally, KBC Group NV boosted its stake in shares of Arcellx by 37.3% during the fourth quarter. KBC Group NV now owns 1,388 shares of the company's stock valued at $106,000 after purchasing an additional 377 shares in the last quarter. Institutional investors own 96.03% of the company's stock.

Insiders Place Their Bets

In other Arcellx news, Director Kavita Patel sold 1,500 shares of the firm's stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $64.57, for a total value of $96,855.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Rami Elghandour sold 38,300 shares of the business's stock in a transaction that occurred on Wednesday, February 26th. The stock was sold at an average price of $62.02, for a total value of $2,375,366.00. Following the sale, the insider now directly owns 149,186 shares of the company's stock, valued at $9,252,515.72. This represents a 20.43 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 54,455 shares of company stock worth $3,408,458. 6.24% of the stock is owned by corporate insiders.

Arcellx Stock Up 2.2 %

NASDAQ ACLX traded up $1.33 on Friday, hitting $62.02. The company's stock had a trading volume of 833,012 shares, compared to its average volume of 559,462. Arcellx, Inc. has a 1-year low of $47.88 and a 1-year high of $107.37. The firm has a market cap of $3.41 billion, a PE ratio of -87.35 and a beta of 0.33. The company's 50-day moving average is $64.91 and its 200 day moving average is $75.39.

Arcellx (NASDAQ:ACLX - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.63) by ($0.24). The firm had revenue of $15.27 million during the quarter, compared to analyst estimates of $27.42 million. Arcellx had a negative return on equity of 8.28% and a negative net margin of 25.94%. On average, equities analysts expect that Arcellx, Inc. will post -1.58 EPS for the current year.

Arcellx Company Profile

Arcellx, Inc, together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).